Carl Pepine, MD
Cardiovascular Disease · Gainesville, FLNPI 1033124789
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $76,858 of the $82,684 with a category attached, or 93.0%. Biocardia, Inc. accounts for 67.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $45,650 and has fallen 92.2% since, to $3,572 in 2024. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $3594.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocardia, Inc.$55K
- Johnson & Johnson$15K
- Janssen Scientific Affairs, LLC$5K
- Idorsia Pharmaceuticals US Inc$4K
- Janssen Global Services, LLC$2K
- Heartflow, Inc.$2K
- plus $357 from 5 others
Across 150 payments — averaging $2998.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$334K
- Janssen Research & Development, LLC$54K
- GE HealthCare$48K
- Amgen$8K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$76,85893%
- Speaking & faculty fees$3,5404%
- Travel & lodging$1,1231%
- Food & beverage$1,1631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocardia, Inc. | 4 | $55,459 |
| Johnson & Johnson | 10 | $14,675 |
| Janssen Scientific Affairs, LLC | 1 | $5,000 |
| Idorsia Pharmaceuticals US Inc | 1 | $3,540 |
| Janssen Global Services, LLC | 1 | $2,153 |
| Heartflow, Inc. | 1 | $1,500 |
| Medtronic | 1 | $125 |
| Cardiovascular Systems Inc. | 1 | $118 |
| Esperion Therapeutics, Inc. | 1 | $47 |
| Akcea Therapeutics, Inc. | 1 | $36 |
| Novo Nordisk | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tryvio$3,540
- FFRct$1,500
- Resolute$125
- Peripheral Orbital Atherectomy System$118
- Coronary Orbital Atherectomy System$118
How this compares
$82,684 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Gainesville
- Juan ArandaGainesville$212K
- Keith MarchGainesville$176K
- Ann TongGainesville$160K
- Carlos Alviar RestrepoGainesville$104K
- Michael KorenGainesville$97K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.